WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Forecast, Predictions & Price Target

Analyst price target for RARE

Based on 7 analysts offering 12 month price targets for Ultragenyx Pharmaceutical Inc.
Min Forecast
$48.00-0.37%
Avg Forecast
$89.57+85.91%
Max Forecast
$130.00+169.82%

Should I buy or sell RARE stock?

Based on 7 analysts offering ratings for Ultragenyx Pharmaceutical Inc.
Strong Buy
Strong Buy
5 analysts 71.43%
Buy
1 analysts 14.29%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RARE stock forecasts and price targets.

RARE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-21
lockedlocked$00.00+00.00%2024-02-16
lockedlocked$00.00+00.00%2024-02-15
lockedlocked$00.00+00.00%2024-01-30
lockedlocked$00.00+00.00%2023-12-08
Morgan Stanley
Top 10%
91
Strong BuyMaintains$84.00+74.35%2023-11-03
Piper Sandler
Top 11%
90
Strong BuyMaintains$130.00+169.82%2023-10-25

1 of 1

Forecast return on equity

Is RARE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
24.42%

Forecast return on assets

Is RARE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RARE revenue forecast

What is RARE's revenue in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$512.8M+18.1%
Avg 2 year Forecast
$634.3M+46.08%
Avg 3 year Forecast
$885.7M+103.97%
RARE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RARE revenue growth forecast

How is RARE forecast to perform vs Biotechnology companies and vs the US market?
Company
25.31%
Industry
48.24%
Market
9.9%
RARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RARE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RARE$48.18$89.57+85.91%Strong Buy
FOLD$13.56$18.00+32.74%Strong Buy
IOVA$15.77$23.60+49.65%Strong Buy
INSM$28.24$45.00+59.35%Strong Buy
AXSM$82.11$124.00+51.02%Strong Buy

Ultragenyx Pharmaceutical Stock Forecast FAQ

Is Ultragenyx Pharmaceutical Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: RARE) stock is to Strong Buy RARE stock.

Out of 7 analysts, 5 (71.43%) are recommending RARE as a Strong Buy, 1 (14.29%) are recommending RARE as a Buy, 1 (14.29%) are recommending RARE as a Hold, 0 (0%) are recommending RARE as a Sell, and 0 (0%) are recommending RARE as a Strong Sell.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

What is RARE's revenue growth forecast for 2024-2026?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 25.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.24%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Ultragenyx Pharmaceutical's revenue in 2024 is $434,249,000.On average, 8 Wall Street analysts forecast RARE's revenue for 2024 to be $42,225,033,721, with the lowest RARE revenue forecast at $41,176,900,426, and the highest RARE revenue forecast at $43,638,737,467. On average, 6 Wall Street analysts forecast RARE's revenue for 2025 to be $52,229,313,706, with the lowest RARE revenue forecast at $46,901,700,743, and the highest RARE revenue forecast at $58,399,879,432.

In 2026, RARE is forecast to generate $72,928,011,403 in revenue, with the lowest revenue forecast at $56,866,788,940 and the highest revenue forecast at $86,026,795,848.

What is RARE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RARE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RARE's Price Target?

According to 7 Wall Street analysts that have issued a 1 year RARE price target, the average RARE price target is $89.57, with the highest RARE stock price forecast at $130.00 and the lowest RARE stock price forecast at $48.00.

On average, Wall Street analysts predict that Ultragenyx Pharmaceutical's share price could reach $89.57 by Feb 21, 2025. The average Ultragenyx Pharmaceutical stock price prediction forecasts a potential upside of 85.91% from the current RARE share price of $48.18.

What is RARE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RARE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.